New targeted drug shows promise for Tough-to-Treat melanoma

NCT ID NCT03420508

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a new drug called ensartinib in people with advanced melanoma that has a specific genetic abnormality (ALK). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 weeks. Participants must be 18 or older and have already tried other treatments like immunotherapy. The study is currently active but no longer recruiting new participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester

    East White Plains, New York, 10604, United States